Interview with a FDA Process expert..., page-63

An interesting read. I hope somebody might be trialling iPPS for the COVID-19 patients. However I believe that the area of inflammatory bowel disease featuring ulcerative colitis as well as crohns disease should be high on the company’s focus. OA is our major present interest. I think we should get data on iPPS and these two diseases. I would outsource the drug to other interests but retain majority ownership. These conditions cannot wait 3 or 4 years to find out if iPPS is a significant good treatment. It would be of no cost to Paradigm as no doubt grants could be available. We need data. Positive data would help the SP as well. This area of treatment is massive and could rival OA.